REG - Novacyt S.A. - Directorate Change

Novacyt SAAnnouncement

31/10/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241031:nRSe3166Ka&default-theme=true

RNS Number : 3166K  Novacyt S.A.  31 October 2024

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

Directorate Change

Dr Ian Gilham appointed as Non-Executive Director

 

Paris, France, Eastleigh and Manchester, UK - 31 October 2024
- Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular
diagnostics company with a broad portfolio of integrated technologies and
services, announces the appointment of Dr Ian Gilham as a Non-Executive
Director with immediate effect. Dr Gilham will become a Board Director of the
Company, subject to shareholder approval, at the Company's Annual General
Meeting.

 

Ian has a wealth of experience in AIM-listed life sciences companies, with an
international track record in the research, development and commercialisation
of diagnostic products that will further strengthen the expertise of the
Novacyt Board. He currently holds roles as Non-Executive Chairman of
AIM-listed Genedrive PLC, Chair of Trustees for LifeArc, a self-funded medical
research charity, Non-Executive Chairman of Pelago Bioscience AB, a life
sciences tools business based in Stockholm and Non-Executive Chairman of
RevoNA Bio, a University of Portsmouth spinout life sciences tools company.
Ian has previously held Board positions at Aptamer Group PLC, Horizon
Discovery PLC, Cytox Ltd, Elucigene Ltd, Multiplicom n.v, Biosufit s.a,
Vernalis plc, Concepta Diagnostics Ltd and was CEO of Axis-Shield PLC.

 

Dr Ian Gilham, Non-Executive Director of Novacyt S.A.

 

Lyn Rees, CEO of Novacyt, commented: "It is a pleasure to welcome Ian to the
Board of Novacyt. Ian has worked with a number of successful AIM-listed life
sciences companies and we look forward to utilising his expertise as we
further optimise and strengthen the Novacyt Group."

 

Additional Information

The following information is disclosed pursuant to Rule 17 and Schedule Two
paragraph (g) of the AIM Rules for Companies in relation to Ian David Gilham
aged 64.

 

 Current Directorships / Partnerships  Former Directorships / Partnerships within the last 5 years
 Genedrive Plc                         Aptamer Group Plc

 LifeArc                               BIOSURFIT s.a

 Pelago Bioscience AB                  Cytox Limited

 Revona Bio Ltd                        Horizon Discovery Group Limited (Formerly Horizon Discovery Plc)

 Stowheath Limited                     Revvity Discovery Limited (Formerly Horizon Discovery Limited)

 

On 4 January 2024, Cytox Limited, a company which Ian Gilham was previously a
director of, appointed a liquidator in connection with a creditors voluntary
winding up.  No notice of administrators' proposal has yet been filed
although the business was estimated to have a deficiency as regards creditors
of £257,405.

 

Save as disclosed above, there is no further information to be disclosed in
respect of the above appointment pursuant to Rule 17 and Schedule 2 paragraph
(g) of the AIM Rules for Companies.

 

Contacts

 

 Novacyt SA                                                              https://novacyt.com/investors (https://novacyt.com/investors/)
 Lyn Rees, Chief Executive Officer                                        Via Walbrook PR
 Steve Gibson, Chief Financial Officer

 SP Angel Corporate Finance LLP (Nominated Adviser and Broker)                                                    +44 (0)20 3470 0470
 Matthew Johnson / Charlie Bouverat (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Deutsche Numis (Joint Broker)                                                                                    +44 (0)20 7260 1000
 Freddie Barnfield / Duncan Monteith / Michael Palser

 Allegra Finance (French Listing Sponsor)       +33 (1) 42 22 10 10

                                             r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) /
 Rémi Durgetto / Yannick Petit                 y.petit@allegrafinance.com (mailto:y.petit@allegrafinance.com)

 Walbrook PR (Financial PR & IR)                                         +44 (0)20 7933 8780 or novacyt@walbrookpr.com (mailto:novacyt@walbrookpr.com)

 Paul McManus / Lianne Applegarth                                        +44 (0)7980 541 893 / +44 (0)7584 391 303

 Phillip Marriage / Alice Woodings                                        +44 (0)7867 984 082 / +44 (0)7407 804 654

 

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad
portfolio of integrated technologies and services, primarily focused on the
delivery of genomic medicine. The Company develops, manufactures, and
commercialises a range of molecular assays and instrumentation to deliver
workflows and services that enable seamless end-to-end solutions from sample
to result across multiple sectors including human health, animal health and
environmental.

 

The Company is divided into three business segments:

 

 Clinical             Broad portfolio of human clinical in vitro diagnostic products, workflows and
                      services focused on three therapeutic areas:

                      ·    Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy
                      tests

                      ·    Precision Medicine: DPYD genotyping assay

                      ·    Infectious Diseases: Winterplex, multiplex winter respiratory PCR
                      panel

 Instrumentation      Portfolio of next generation size selection DNA sample preparation platforms
                      and rapid PCR machines, including:

                      ·    Ranger® Technology: automated DNA sample preparation and target
                      enrichment technology

                      ·    genesig q16 and q32 real-time quantitative PCR (qPCR) instruments

 Research Use Only    Range of services for the life sciences industry:

                      ·    Design, manufacture, and supply of high-performance qPCR assays and
                      workflows for use in human health, agriculture, veterinary and environmental,
                      to support global health organisations and the research industry

                      ·    Pharmaceutical research services: whole genome sequencing (WGS) /
                      whole exome sequencing (WES)

 

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the
UK (in Eastleigh and Manchester), Singapore, the US and Canada and has a
commercial presence in over 65 countries. The Company is listed on the London
Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext
Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAMMBBTMTJJTJI